Transcode Therapeutics

Transcode Therapeutics Debt

The Debt of Transcode Therapeutics (RNAZ) as of Oct 20, 2026 is 38,291.00 USD. In the previous year, Debt was 450,571.00 USD — a change of -91.50% (lower).

Debt

38,291.00USD

YoY

-91.50%

Last updated:

In 2024, Transcode Therapeutics's total debt was 38,291.00 USD, a -91.50% change from the 450,571.00 USD total debt recorded in the previous year.

The Transcode Therapeutics Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
471,900.00 USD
Jan 1, 2019
927,810.00 USD
Jan 1, 2020
2.09 M USD
Jan 1, 2021
2.02 M USD
Jan 1, 2023
450,571.00 USD
Jan 1, 2024
38,291.00 USD
The Transcode Therapeutics Debt history
YEARDebtYoY
38,291.00USD-91.50%
450,571.00USD-77.65%
2.02 MUSD-3.37%
2.09 MUSD+124.90%
927,810.00USD+96.61%
471,900.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Transcode Therapeutics Stock analysis

What does Transcode Therapeutics do? Transcode Therapeutics is one of the most popular companies on Eulerpool.

Debt Details

Understanding Transcode Therapeutics's Debt Structure

Transcode Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Transcode Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Transcode Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Transcode Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Transcode Therapeutics stock

Debt of Transcode Therapeutics is 38,291.00 USD in 2024.

Debt of Transcode Therapeutics changed from 450,571.00 USD to 38,291.00 USD, representing a -91.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Transcode Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Transcode Therapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transcode Therapeutics